Methotrexaat Sandoz (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This limits the supply of one‑carbon units needed for DNA, RNA and protein synthesis, particularly affecting rapidly dividing cells such as immune cells and cancer cells, thereby reducing inflammation and tumor growth.

The specific dose of Methotrexaat Sandoz is determined by the prescribing clinician based on the patient’s condition, disease severity, renal and hepatic function, and other individual factors. Dosage regimens vary widely across the approved indications and must be individualized.

Methotrexaat Sandoz is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug may be excreted in milk; therefore, use is generally discouraged unless the benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and import documentation.

Methotrexaat Sandoz shares the same mechanism as other folate antagonists such as pemetrexed, but methotrexate has a broader range of approved indications, including autoimmune diseases and several cancers. Its dosing flexibility and long‑standing clinical experience make it a widely used option, though safety monitoring requirements are similar across the class.

Methotrexaat Sandoz should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve tablet integrity and potency throughout its shelf life.

Methotrexaat Sandoz is supplied as oral tablets that are swallowed whole with water. The prescribing clinician determines the dosing schedule, which may be daily, weekly or as part of a treatment cycle, depending on the specific indication and patient response.

Serious risks include severe liver toxicity, pulmonary fibrosis, renal failure, and profound bone‑marrow suppression leading to pancytopenia. Patients should be monitored regularly for liver enzymes, renal function, lung symptoms and blood counts to detect these complications early.

Methotrexaat Sandoz is contraindicated in patients with known hypersensitivity to methotrexate or any excipients, in pregnant women, and in individuals with severe hepatic or renal impairment. Caution is also advised for patients with active infections or compromised immune systems.